Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12964192 | 0.89 | MAPK14 (0.47) | MAPK14MAPK11SSTR5RIPK2CYP3A4 | |
| SCHEMBL2216787 | 0.87 | MAPK14 (0.48) | MAPK14MAPK11SSTR5PAX8CYP3A4 | |
| SCHEMBL1386596 | 0.86 | LMNA (0.55) | MAPK14MAPK11SSTR5RIPK2LMNA | |
| SCHEMBL2214450 | 0.84 | MAPK14 (0.46) | MAPK14MAPK11SSTR5RIPK2PAX8 | |
| SCHEMBL2218015 | 0.82 | LMNA (0.45) | MAPK14LMNA | |
| SCHEMBL2220451 | 0.78 | MAPK14 (0.48) | MAPK14MAPK11SSTR5RIPK2CYP3A4 | |
| SCHEMBL11965674 | 0.77 | MAPK14 (0.48) | MAPK14MAPK11LMNACYP3A4CYP2C9 | |
| SCHEMBL1385239 | 0.77 | MAPK14 (0.49) | MAPK14MAPK11SSTR5RIPK2 | |
| SCHEMBL1416943 | 0.76 | MAPK14 (0.47) | MAPK14MAPK11SSTR5LMNACYP3A4 | |
| SCHEMBL1382659 | 0.76 | MAPK14 (0.50) | MAPK14MAPK11PAX8CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641764-B1 | 5-MEMBERED HETEROCYCLE-BASED P38 KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-07-27 | — | — | EP | claimed |